Cargando…
Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation
Dendritic cell (DC)–based immunotherapies are believed to help eradicate residual tumor cells, including hepatocellular carcinoma (HCC). Here, we assessed the safety and clinical response to OK432-stimulated monocyte-derived DCs (MoDCs) in treating HCC after radiofrequency ablation (RFA). MoDCs were...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226894/ https://www.ncbi.nlm.nih.gov/pubmed/32413834 http://dx.doi.org/10.1016/j.tranon.2020.100777 |
_version_ | 1783534386408325120 |
---|---|
author | Kitahara, Masaaki Mizukoshi, Eishiro Terashima, Takeshi Nakagawa, Hidetoshi Horii, Rika Iida, Noriho Arai, Kuniaki Yamashita, Taro Sakai, Yoshio Yamashita, Tatsuya Honda, Masao Nakamoto, Yasunari Kaneko, Shuichi |
author_facet | Kitahara, Masaaki Mizukoshi, Eishiro Terashima, Takeshi Nakagawa, Hidetoshi Horii, Rika Iida, Noriho Arai, Kuniaki Yamashita, Taro Sakai, Yoshio Yamashita, Tatsuya Honda, Masao Nakamoto, Yasunari Kaneko, Shuichi |
author_sort | Kitahara, Masaaki |
collection | PubMed |
description | Dendritic cell (DC)–based immunotherapies are believed to help eradicate residual tumor cells, including hepatocellular carcinoma (HCC). Here, we assessed the safety and clinical response to OK432-stimulated monocyte-derived DCs (MoDCs) in treating HCC after radiofrequency ablation (RFA). MoDCs were derived from 30 HCC patients in the presence of interleukin-4 and granulocyte-macrophage colony stimulating factor for 5 days and then cultured for 2 more days in the medium (basic protocol) or stimulated with OK432. On day 7, DCs were harvested and percutaneously injected into HCC tumors after RFA. We observed no grade 3 or 4 National Cancer Institute Common Toxicity Criteria adverse events. Kaplan-Meier analysis indicated that patients treated with RFA + OK432-stimulated DCs transfer had longer recurrence-free survival than those treated with RFA + basic-protocol DCs (median: 24.8 vs 13.0 months; P = .003). RFA with DC infusion can enhance various tumor-associated antigen (TAA)–specific T-cell responses. Additionally, the 5-year RFS rate for patients with significantly increased TAA-specific T-cell responses was much higher than for other patients (50.0% vs. 7.7%; P = .030). Our study provides useful information for development of HCC immunotherapies (trial registration: UMIN000001701). |
format | Online Article Text |
id | pubmed-7226894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72268942020-05-18 Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation Kitahara, Masaaki Mizukoshi, Eishiro Terashima, Takeshi Nakagawa, Hidetoshi Horii, Rika Iida, Noriho Arai, Kuniaki Yamashita, Taro Sakai, Yoshio Yamashita, Tatsuya Honda, Masao Nakamoto, Yasunari Kaneko, Shuichi Transl Oncol Original article Dendritic cell (DC)–based immunotherapies are believed to help eradicate residual tumor cells, including hepatocellular carcinoma (HCC). Here, we assessed the safety and clinical response to OK432-stimulated monocyte-derived DCs (MoDCs) in treating HCC after radiofrequency ablation (RFA). MoDCs were derived from 30 HCC patients in the presence of interleukin-4 and granulocyte-macrophage colony stimulating factor for 5 days and then cultured for 2 more days in the medium (basic protocol) or stimulated with OK432. On day 7, DCs were harvested and percutaneously injected into HCC tumors after RFA. We observed no grade 3 or 4 National Cancer Institute Common Toxicity Criteria adverse events. Kaplan-Meier analysis indicated that patients treated with RFA + OK432-stimulated DCs transfer had longer recurrence-free survival than those treated with RFA + basic-protocol DCs (median: 24.8 vs 13.0 months; P = .003). RFA with DC infusion can enhance various tumor-associated antigen (TAA)–specific T-cell responses. Additionally, the 5-year RFS rate for patients with significantly increased TAA-specific T-cell responses was much higher than for other patients (50.0% vs. 7.7%; P = .030). Our study provides useful information for development of HCC immunotherapies (trial registration: UMIN000001701). Neoplasia Press 2020-05-12 /pmc/articles/PMC7226894/ /pubmed/32413834 http://dx.doi.org/10.1016/j.tranon.2020.100777 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Kitahara, Masaaki Mizukoshi, Eishiro Terashima, Takeshi Nakagawa, Hidetoshi Horii, Rika Iida, Noriho Arai, Kuniaki Yamashita, Taro Sakai, Yoshio Yamashita, Tatsuya Honda, Masao Nakamoto, Yasunari Kaneko, Shuichi Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
title | Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
title_full | Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
title_fullStr | Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
title_full_unstemmed | Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
title_short | Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
title_sort | safety and long-term outcome of intratumoral injection of ok432-stimulated dendritic cells for hepatocellular carcinomas after radiofrequency ablation |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226894/ https://www.ncbi.nlm.nih.gov/pubmed/32413834 http://dx.doi.org/10.1016/j.tranon.2020.100777 |
work_keys_str_mv | AT kitaharamasaaki safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT mizukoshieishiro safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT terashimatakeshi safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT nakagawahidetoshi safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT horiirika safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT iidanoriho safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT araikuniaki safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT yamashitataro safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT sakaiyoshio safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT yamashitatatsuya safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT hondamasao safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT nakamotoyasunari safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation AT kanekoshuichi safetyandlongtermoutcomeofintratumoralinjectionofok432stimulateddendriticcellsforhepatocellularcarcinomasafterradiofrequencyablation |